Article Date: 06 Nov 2009
David Koos, Chairman and CEO of Entest BioMedical, Inc. (OTCBB: ENTB), stated that the Company's unique treatments for Chronic Obstructive Pulmonary Disease (COPD), currently in development, can lead to substantial revenue opportunities. According to Koos, "Current treatment for COPD is aimed at improving quality of life, not curing the illness. It is Entest's goal to reverse the damage from COPD. If successful, Entest stands to profit substantially from the money currently spent on maintenance treatments that are not cures."
The Company stated that over the next 5 years over $170 billion will be spent on treating COPD in the United States. Currently COPD is the 4th leading cause of death in the United States and is projected to become the 3rd leading cause of death in the US by 2020. It is estimated that COPD medical related costs will be in excess of $800 billion during the next 20 years.
David Koos also stated, "It is clear that both in the near term and further out any company demonstrating efficacy in treating COPD has a great chance to participate in the billions of dollars that are and will be spent treating COPD. We believe our patent pending treatment model represents not only a 'mitigating treatment' but could provide a 'regenerative treatment' for patients. COPD is a progressive, non-reversible disease. Our researchers believe using a photoceutical device to direct stem cells to targeted damaged lung tissue may actually reverse the impact of COPD."
The uniqueness of Entest's model involves "painting" damaged tissue with the photoceutical device, which then guides the stem cells to the desired areas. This focused approach allows for concentration of the stem cell treatment. This advanced treatment approach relies on stem cell therapy which requires FDA approval and photoceutical devices that are currently being used in treating other illnesses.
Entest is seeking grant funding in excess of $3 million to support its research and is applying for government development contracts.
Source
Entest BioMedical Inc.
David Koos, Chairman and CEO of Entest BioMedical, Inc. (OTCBB: ENTB), stated that the Company's unique treatments for Chronic Obstructive Pulmonary Disease (COPD), currently in development, can lead to substantial revenue opportunities. According to Koos, "Current treatment for COPD is aimed at improving quality of life, not curing the illness. It is Entest's goal to reverse the damage from COPD. If successful, Entest stands to profit substantially from the money currently spent on maintenance treatments that are not cures."
The Company stated that over the next 5 years over $170 billion will be spent on treating COPD in the United States. Currently COPD is the 4th leading cause of death in the United States and is projected to become the 3rd leading cause of death in the US by 2020. It is estimated that COPD medical related costs will be in excess of $800 billion during the next 20 years.
David Koos also stated, "It is clear that both in the near term and further out any company demonstrating efficacy in treating COPD has a great chance to participate in the billions of dollars that are and will be spent treating COPD. We believe our patent pending treatment model represents not only a 'mitigating treatment' but could provide a 'regenerative treatment' for patients. COPD is a progressive, non-reversible disease. Our researchers believe using a photoceutical device to direct stem cells to targeted damaged lung tissue may actually reverse the impact of COPD."
The uniqueness of Entest's model involves "painting" damaged tissue with the photoceutical device, which then guides the stem cells to the desired areas. This focused approach allows for concentration of the stem cell treatment. This advanced treatment approach relies on stem cell therapy which requires FDA approval and photoceutical devices that are currently being used in treating other illnesses.
Entest is seeking grant funding in excess of $3 million to support its research and is applying for government development contracts.
Source
Entest BioMedical Inc.